## HCA: HCA Healthcare, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.22 indicates fundamental undervaluation. Quality metrics strong (ROE 136%, ROA 12%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-4.7% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($444.37)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Artificial Intelligence at HCA Healthcare â€“ Two Use Cases**
- Source: Emerj Artificial Intelligence Research | 20251208T111621 | Bullish | Relevance: 99%
-  HCA Healthcare is leveraging AI in two key areas. First, they partnered with Google Cloud and Commure to implement generative AI for clinical documentation, aiming to improve workflow efficiency and free up clinicians' time. Second, they collaborated with GE HealthCare to develop CareIntellect for Perinatal, a cloud-based platform utilizing AI and predictive analytics to centralize maternal and fetal data, detect risks earlier, and strengthen perinatal outcomes.

**2. Amundi Boosts Holdings in HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251208T130804 | Bullish | Relevance: 98%
-  Amundi significantly increased its stake in HCA Healthcare by 36.2% in Q2, bringing its total holdings to 394,665 shares valued at $149.2 million. This comes as HCA Healthcare reported strong Q3 earnings, surpassing expectations with an EPS of $6.96 and revenue of $19.16 billion, leading to several analyst price target increases and a "Moderate Buy" consensus rating. Despite an insider sale by EVP Michael R. McAlevey, institutional investors collectively own a substantial 62.7% of the company, and the company announced a quarterly dividend of $0.72 per share.

**3. Natixis Has $21.56 Million Position in HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251209T130812 | Somewhat-Bullish | Relevance: 98%
-  Natixis reduced its stake in HCA Healthcare, Inc. by 4.3% in Q2, now holding 56,272 shares valued at $21.56 million. Other institutional investors have also adjusted their positions, and an insider recently sold a significant number of shares. HCA Healthcare reported strong quarterly earnings, surpassing analyst estimates, and announced a quarterly dividend.

**4. HCA taps new VP of community engagement**
- Source: Healthcare Dive | 20251209T154515 | Bullish | Relevance: 98%
-  HCA Healthcare has appointed Virginia Tenpenny as its new vice president of community engagement, overseeing charitable investments, outreach, and strategic partnerships. Tenpenny will join HCA on January 12, replacing Joanne Pulles, who is retiring after 26 years. In her new role, Tenpenny will build on HCA's significant community contributions, which exceeded $48.5 million in enterprise giving and over $18 million from employee matching funds in 2024.

**5. Cerity Partners LLC Purchases 7,984 Shares of HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251210T100855 | Bullish | Relevance: 98%
- Cerity Partners LLC increased its stake in HCA Healthcare, Inc. by 25.9%, purchasing an additional 7,984 shares and bringing their total holdings to $14,875,000. Other institutional investors have also modified their positions. The article also notes an insider stock sale by EVP Michael R. Mcalevey and discusses HCA Healthcare's recent financial performance, dividend announcement, and analyst ratings.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-13 | Wells Fargo | $431 | $412 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-13 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($3.12M) |
| Sells | 4 ($14.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 29.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 6.5% (-3.8%)
- Blackrock Inc.: 5.5% (-3.7%)
- Sanders Capital, LLC: 4.7% (-3.9%)
- State Street Corpora: 3.3% (-5.9%)
- JPMORGAN CHASE & CO: 2.6% (+82.2%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-4.7% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $15M sold (4 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.22 suggests fair value with growth premium. Forward P/E 15.8x stretched relative to 8% growth. Quality metrics strong (ROE 136%, ROA 12%). Balance sheet: $3.1B free cash flow. Insider selling cluster ($14.8M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $109.7B |
| Beta | 1.37 |
| 52W Range | $289.98 - $520.00 |
| Short Interest | 3.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.22 |
| Forward P/E | 15.8 |
| Current P/E | 17.0 |
| YoY Growth | 7.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -1.7% to -6.4% (-4.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 10.4pp (needs >4.0% for momentum thesis). AM_20 at -4.0% indicates price below own 20MA trend. Long-term uptrend intact (above SMA200 at 1.20x) but short-term weakness (below SMA20). MACD histogram bearish (-4.46), momentum weakening. RSI neutral at 43.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -6.38% (CS: 8) | Weak |
| RSI_14 | 42.9 | Neutral |
| MACD Histogram | -4.46 | Bearish |
| vs SMA20 | 0.960x | Below |
| vs SMA50 | 1.016x | Above |
| vs SMA200 | 1.201x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $468.73
- **Stop Loss:** $444.37 (5.2% risk)
- **Target:** $517.45 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 20
- **Position Value:** $9,374.60
- **Portfolio %:** 9.37%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with signs of improving risk appetite. Multiple major banks lowering prime rates suggest a dovish tilt in financial conditions ahead of the FOMC, while volatility remains subdued and breadth is moderate. Key drivers are easing lending rates, stable macro data, and improving sentiment, but selectivity is needed due to sector divergences.*

### Earnings

**Next:** 2026-01-23 (Est: $7.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.73 | $6.96 | +21.6% |
| 2025Q2 | $6.32 | $6.84 | +8.2% |
| 2025Q1 | $5.75 | $6.45 | +12.1% |
| 2024Q4 | $6.14 | $6.22 | +1.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*